KalVista Pharmaceuticals (KALV) Debt Ratio (2014 - 2016)

KalVista Pharmaceuticals (KALV) reported Debt Ratio of 0.09 for Q1 2016, down 83.88% on a YoY basis from 0.58 in Q2 2015, and up 15.37% sequentially from 0.08 in Q4 2015.

KalVista Pharmaceuticals (KALV) Debt Ratio (2014 - 2016) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 3 years of Debt Ratio data on file, last reported at 0.09 in Q1 2016.

  • For the quarter ending Q1 2016, Debt Ratio fell 83.88% year-over-year to 0.09; the trailing twelve-month figure through Mar 2016 stood at 0.09 (down 83.88% YoY), and the FY2016 full-year result was 0.01, changed N/A from the prior year.
  • Debt Ratio advanced to 0.09 in Q1 2016, from 0.08 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.67 in Q4 2014 to a low of 0.07 in Q2 2015.
  • A 3-year average of 0.26 and a median of 0.09 in 2015 frame the typical range for Debt Ratio.
  • Across the five-year window, Debt Ratio slumped 87.84% in 2015 and plunged 83.88% in 2016, its largest moves.
  • Tracing KALV's Debt Ratio over 3 years: stood at 0.67 in 2014, then tumbled by 87.84% to 0.08 in 2015, then rose by 15.37% to 0.09 in 2016.
  • Business Quant data shows KALV's Debt Ratio at 0.09 in Q1 2016, 0.08 in Q4 2015, and 0.07 in Q3 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 1.41
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.11
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.05
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 KalVista Pharmaceuticals 1.36 Bn 1.36 Bn 49.41 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2016 0.09
Dec 31, 2015 0.08
Sep 30, 2015 0.07
Jun 30, 2015 0.07
Mar 31, 2015 0.58
Dec 31, 2014 0.67